Tvardi Therapeutics, Inc. (TVRD) Reports New Preclinical UC Data Supporting STAT3 Inhibitors

Tvardi published preclinical data showing its oral STAT3 inhibitors reached high colon exposure and modulated disease biology in UC models, including preventing adenocarcinomas in an AOM-DSS mouse model, supporting advancement of TTI-109 in UC.Material DetailsContext by AI AnalystThis is early-stag…